Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754641 | 0.88 | TSHR (0.36) | ALDH1A1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL25754634 | 0.87 | — | — | |
| SCHEMBL25754647 | 0.73 | DPP8 (0.47) | L3MBTL1ALDH1A1KDM4ECYP2C19MEN1 | |
| SCHEMBL12726849 | 0.72 | HRH3 (0.42) | HRH3L3MBTL1ALDH1A1TSHRRECQL | |
| SCHEMBL25754645 | 0.71 | HRH3 (0.40) | HRH3L3MBTL1ALDH1A1TSHRRECQL | |
| SCHEMBL13656174 | 0.70 | MEN1 (0.41) | HRH3L3MBTL1ALDH1A1TSHRRECQL | |
| SCHEMBL13405105 | 0.69 | CHRM1 (0.51) | L3MBTL1ALDH1A1TSHRRECQLKDM4E | |
| SCHEMBL25754390 | 0.68 | LMNA (0.35) | HRH3L3MBTL1LMNA | |
| SCHEMBL25754397 | 0.68 | ANPEP (0.34) | KDM4ECYP2D6CYP2C19MEN1LMNA | |
| SCHEMBL25754643 | 0.67 | SIGMAR1 (0.37) | ALDH1A1TSHRKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HRH3 1596/4885L3MBTL1 480/4885ALDH1A1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.